Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
<h4>Background</h4>The conditions of diminished ovarian reserve and primary ovarian insufficiency, characterized by poor fertility outcomes, currently comprise a major challenge in reproductive medicine, particularly in vitro fertilization. Currently in the IVF industry, blastocyst devel...
Main Authors: | Sheela Sadruddin, Brian Barnett, Lowell Ku, Dara Havemann, Sara Mucowski, Richard Herrington, Warren Burggren |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0239779 |
Similar Items
-
Bivariate analysis of basal serum anti-Mullerian hormone measurements and human blastocyst development after IVF.
by: Sills, E, et al.
Published: (2011) -
Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
by: Sills E Scott, et al.
Published: (2011-12-01) -
Discordant anti-müllerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth?
by: Shunping Wang, et al.
Published: (2018-07-01) -
Anti-Müllerian hormone as a predictor of IVF treatment
by: Mehrafza M, et al.
Published: (2012-09-01) -
A study to correlate serum anti mullerian hormone, basal follicle stimulating hormone and antral follicle count in primary infertility as a measure of ovarian reserve
by: Shruthi A, et al.
Published: (2022-07-01)